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The prognostic significance of Cdc6 
and Cdt1 in breast cancer
Ravikiran Mahadevappa1, Henrique Neves1, Shun Ming Yuen1, Yuchen Bai1, Cian M. 
McCrudden2, Hiu Fung Yuen3, Qing Wen4, Shu Dong Zhang5 & Hang Fai Kwok1
DNA replication is a critical step in cell proliferation. Overexpression of MCM2-7 genes correlated with 
poor prognosis in breast cancer patients. However, the roles of Cdc6 and Cdt1, which work with MCMs 
to regulate DNA replication, in breast cancers are largely unknown. In the present study, we have 
shown that the expression levels of Cdc6 and Cdt1 were both significantly correlated with an increasing 
number of MCM2-7 genes overexpression. Both Cdc6 and Cdt1, when expressed in a high level, alone 
or in combination, were significantly associated with poorer survival in the breast cancer patient cohort 
(n = 1441). In line with this finding, the expression of Cdc6 and Cdt1 was upregulated in breast cancer 
cells compared to normal breast epithelial cells. Expression of Cdc6 and Cdt1 was significantly higher in 
ER negative breast cancer, and was suppressed when ER signalling was inhibited either by tamoxifen 
in vitro or letrozole in human subjects. Importantly, breast cancer patients who responded to letrozole 
expressed significantly lower Cdc6 than those patients who did not respond. Our results suggest that 
Cdc6 is a potential prognostic marker and therapeutic target in breast cancer patients.
DNA replication is an all-or-nothing process; once DNA replication begins, it proceeds to completion and a 
DNA segment is never replicated twice in one cell cycle1. The precision of timely initiation of DNA replication 
is very important for preventing abnormal inheritance of genomic pool to daughter cells. To avoid undesirable 
consequences such as under or over DNA replication, the entire process is tightly regulated by a multi-subunit 
initiator protein complex known as “Pre-replication complex (pre-RC)” or “Licensing complex”. This complex 
consists of origin-recognition complex (ORC; consists of Orc1 to 6), protein Cell division cycle – 6 (Cdc6), pro-
tein Chromatin Licensing and DNA Replication Factor 1 (Cdt1) and Minichromosome maintenance proteins 
(MCMs). Establishment of the regulatory process requires a stepwise assembly of ORC, CDC6, CDT1 and MCMs 
in the replication origin1.
During late M phase and early G1 phase of the cell cycle, ORC binds to the DNA replication origin which acts 
as a platform for recruiting Cdc6 and Cdt12, which then recruits MCMs onto the origin for initiation of DNA 
replication. When the MCMs move on the chromatin as elongation proceeds, the origin is then converted to 
an unlicensed state by the binding of Geminin to Cdt1 to prevent DNA re-replication1, 3. Other than Geminin, 
cyclin-dependent kinases (CDKs) also play an important role in regulating the initiation of DNA replication. 
CDK activity increases from the onset of S-phase to M-phase leading to phosphorylation of licensing factors to 
prevent re-licensing1, 3. After DNA duplication and chromosome segregation have been completed, CDKs are 
then inactivated and Geminin is degraded to prepare for a new round of DNA replication1. Genetic alterations 
leading to deletion or overexpression of these proteins have severe consequences on genomic stability and cell 
proliferation. Deletion of either Cdc6 or Cdt1 prevents normal association of MCMs with chromatin during G1 
phase thereby stalling cell cycle progression4. In-contrast, over-expression of Cdt1 is observed to over-ride cell 
control checkpoints initiating DNA re-replication through activation of ATM/ATR checkpoint pathways5.
Overexpression of Cdc6 and Cdt1 has been shown to contribute to oncogenesis6, 7 and their upregulations are 
linked to cancer progression in various types of cancer8–13. Cdc6 has been shown to be regulated by estrogen14, 
and is downregulated in methionine-mediated inhibition of cell proliferation15. However, little is known regard-
ing the prognostic significance of Cdc6 and Cdt1 in breast cancer.
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We have previously shown that MCMs play an important role in breast cancer progression and that the 
over-expression of multiple MCMs is significantly correlated with poor prognosis in breast cancer patients16. 
These results, together with others indicate that MCMs contribute to the development and progression of breast 
cancer17–20, support the hypothesis that increased expression of genes correlated with DNA replication licensing 
may be a prognostic marker and a therapeutic target for breast cancer21. Since Cdc6, Cdt1 and Orc1 work coop-
eratively with MCM2-7 to initiate DNA replication, in our current study we have investigated whether there are 
associations between these three genes and clinicopathological parameters or expression of MCMs in breast 
cancer.
Results
The association between expressions of MCM2-7, Cdc6, Cdt1 and Orc1 in breast cancer speci-
mens. Previously, we have shown that overexpression of increasing numbers of MCM2-7 genes is associated 
with poor prognosis in breast cancer patients. Since Cdc6, Cdt1 and Orc1 work cooperatively with MCM2-7 to 
initiate DNA replication, we have investigated whether there are associations between the numbers of overex-
pressed MCM2-7 genes and expression of these three genes in breast cancer specimens. There was a statistically 
significant positive correlation between number of MCM2-7 genes expressed at a high level and Cdc6 expression 
level (Spearman’s rank test, r = 0.435, p < 0.001; Fig. 1A). A similar pattern of correlation was observed when 
Cdt1 expression level was stratified with the number of MCM2-7 genes expressed at high level (Spearman’s rank 
test, r = 0.448, p < 0.001; Fig. 1B). There was also a significant positive correlation between Orc1 expression and 
number of MCM2-7 genes expressed at a high level in breast cancer specimens (spearman’s rank test, r = 0.349, 
p < 0.001; Fig. 1C).
Indeed, we also found a significantly positive correlation among Cdc6, Cdt1 and Orc1 expression levels. 
Expression of Cdc6 was significantly positively correlated with Cdt1 expression (Spearman’s rank test, r = 0.485, 
Figure 1. The expression levels of Cdc6, Cdt1 and Orc1 in breast cancer patients expressing various levels of 
MCM genes. Histograms showing percentage of specimens that expressed different levels of (A) Cdc6, (B) Cdt1 
and (C) Orc1 in six groups of specimens stratified by the number of MCM2-7 genes they overexpress.
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 985  | DOI:10.1038/s41598-017-00998-9
p < 0.001; Fig. 2A) and Orc1 expression (Spearman’s rank test, r = 0.348, p < 0.001; Fig. 2B). Similarly, a signifi-
cantly positive correlation was observed for the expression levels of Cdt1 and Orc1 (r = 0.338; p < 0.001; Fig. 2C).
The association between the expression levels of Cdc6 and Cdt1 and breast cancer patient sur-
vival. We have previously reported a correlation between increasing numbers of MCM genes being overex-
pressed and poor prognosis in breast cancer patients16. Here, we investigated whether Cdc6, Cdt1 or Orc1 also 
confer prognostic value to breast cancer patients. In the combined cohort as described previously16, patients 
whose breast cancer expressed a low level of Cdc6 had a significantly longer survival than those patients whose 
tumors expressed Cdc6 at a high level (Wilcoxon-Gehan test, p < 0.001; Univariate Cox regression, hazard 
ratio = 1.409, 95% confidence interval = 1.192–1.666, p < 0.001; Fig. 3A). Similarly, patients whose tumors 
expressed a low level of Cdt1 had a significantly longer survival time than those whose tumors expressed a high 
level of Cdt1 (Wilcoxon-Gehan test, p = 0.005; Univariate Cox regression, hazard ratio = 1.199, 95% confidence 
interval = 1.016–1.416, p = 0.032; Fig. 3B). The associations between expression level and survival was much 
obvious for CDC6, but less so for Cdt1. Conversely, Orc1 expression was not similarly predictive of survival in the 
combined cohort (Wilcoxon-Gehan test, p = 0.239; Univariate Cox regression, hazard ratio = 1.105, 95% confi-
dence interval = 0.936–1.304, p = 0.241; Fig. 3C).
Interestingly, when we considered Cdt1 and Cdc6 together, patients whose breast cancer expressed both 
Cdt1 and Cdc6 at a high level had a significantly shorter survival time compared to those patients whose breast 
cancer expressed only one of Cdc6 or Cdt1 at a high level (Wilcoxon-Gehan test, p = 0.01), or those patients 
whose breast cancer expressed both Cdc6 and Cdt1 at a low level (Wilcoxon-Gehan test, p < 0.001; Fig. 3D). 
Patients whose tumors expressed either Cdc6 or Cdt1 at a high level also had a shorter survival time compared 
Figure 2. The associations between the expression levels of Cdc6, Cdt1 and Orc1 in breast cancer specimens. 
Histograms showing percentage of specimens that expressed different levels of (A) Cdc6 vs. Cdt1, (B) Cdc6 vs. 
Orc1 and (C) Cdt1 and Orc1, in breast cancer specimens.
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to those whose cancer expressed both Cdc6 and Cdt1 at a low level (Wilcoxon-Gehan test, p = 0.052; Fig. 4D). 
Patients with either high tumoral Cdc6 or Cdt1 had a significantly higher risk of disease progression or death 
than those patients whose tumors expressed both genes at a low level (univariate Cox regression analysis; Hazard 
ratio = 1.259, 95% CI = 1.019–1.555, p = 0.033); this relationship was even more significant when both Cdc6 and 
Cdt1 were highly expressed (Hazard ratio = 1.481, 95% confidence interval = 1.206–1.818, p < 0.001).
More importantly, we also found that the prognostic significance of Cdc6 expression in the breast cancer 
patient cohort was independent of the prognostic significance of MCM2-7 genes. In a multivariate Cox-regression 
Figure 3. Survival analysis of patients who express different levels of Cdc6, Cdt1 and Orc1. Kaplan-Meier 
curves showing survival time of patients who express different levels of (A) Cdc6, (B), Cdt1 and (C) Orc1 in the 
combined breast cancer patient cohort. (D) Kaplan Meier curves showing survival time of patients who express 
different levels of Cdc6 and Cdt1 analyzed in combination in the whole breast cancer patient cohort. Kaplan 
Meier curves showing survival time of patients expressing different levels of Cdc6 in breast cancer cohort 
stratified based on the number of MCM genes they overexpress (E ≤ 3 MCMs overexpressed) and (F ≥ 4 MCMs 
overexpressed).
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analysis using forward condition stepwise approach including MCM2-7 genes, Cdc6, Cdt1, Orc1 as variable fac-
tors, we found that both the number of MCM2-7 genes expressed at high level (Hazard ratio = 1.538, 95% confi-
dence interval = 1.303–1.816, p < 0.001) and Cdc6 (Hazard ratio = 1.419, 95% confidence interval = 1.184–1.699, 
p = 0.025) were independent prognostic factors. We demonstrated in our previous report that patients whose 
tumors express more than three MCM2-7 genes at high level had a poorer prognosis compared to other patients16. 
Indeed, Cdc6 expression was significantly correlated with survival in patients whose cancer expressed three or 
fewer MCM2-7 genes at a high level (Wilcoxon-Gehan test, p = 0.004; Fig. 3E), but not in those patients whose 
cancer expressed four or more MCM2-7 genes at high level (p = 0.425; Fig. 3F). Further investigation is required 
to confirm the interaction between the expressions of CDC6 and MCMs in breast cancer.
We further tested the expression level of Cdc6 and Cdt1 in three breast cancer cell lines; three breast cell lines 
were chosen based on their aggressiveness and ER-positivity as well as their popularity in the literature. A normal 
breast epithelial cell line MCF10A and two malignant breast cancer cell lines, MCF7 and MDA MB231. We found 
that the mRNA expression levels of Cdc6 and Cdt1 were both higher in the two cancer cell lines compared to the 
normal breast epithelial cell line (Fig. 5A and B for Cdc6 and Cdt1, respectively). Similar results were obtained in 
their protein expression levels. As shown in Fig. 5C, expression levels of these two proteins were higher in the two 
cancer cell lines compared to the normal cells. Importantly, the expression of these two genes was correlated with 
proliferative signal. We found that in both MCF7 and MDA MB231 cells, withdrawal of FBS from the medium 
resulted in suppression of Cdc6 and Cdt1 expression (Fig. 5C).
The association between expression levels of Cdc6, Cdt1 and Orc1 with ER status and ER sig-
nalling. Since Estrogen Receptor (ER) plays a significant role in breast cells proliferation, the associations 
between ER status and ER signalling and expression of Cdc6 and Cdt1 were further investigated. Of the 1441 
breast cancer patients in the combined cohort, the ER status of 716 were known (172 cases – ER-negative, 544 
cases – ER-positive). ER negative breast cancer specimens had a higher level expression of Cdc6 compared to 
those specimens with positive ER status (Chi Square test, p < 0.001; Fig. 4A). Similar results were observed for 
Cdt1 (Chi Square test, p < 0.001; Fig. 4B) and Orc1 (Chi Square test, p < 0.001; Fig. 4C).
Figure 4. The association between expression of Cdc6, Cdt1 and Orc1 with different ER status and survival. 
Histograms showing the percentage of patients with various expression levels of (A) Cdc6, (B) Cdt1 and (C) 
Orc1 in patients stratified by ER status. Kaplan-Meier curves showing survival time of patients who express 
different levels of Cdc6 in patients with (D) ER-negative breast cancer and (E) ER-positive breast cancer.
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Interestingly, the association between high Cdc6 expression and patient survival was only observed in 
ER-positive breast cancer patients (Wilcoxon-Gehan test, p = 0.420; Fig. 4D), but not in ER-negative breast can-
cer (Wilcoxon-Gehan test, p = 0.004; Fig. 4E).
The association between expression level of Cdc6 and Cdt1, and the response to letrozole. We 
went on to investigate the impact of inhibited ER signalling on the expression of Cdc6 and Cdt1 in the ER-positive 
MCF7 breast cancer cells and human breast cancer specimens.
In MCF7 cells, both mRNA and protein expressions of Cdc6 were significantly reduced by treatment with 
tamoxifen, an ER inhibitor, for 12 and 24 hours (Fig. 6A and B). Similar results were observed for Cdt1 (Fig. 6C 
and D). These results suggest that inhibition of ER signalling resulted in suppression of Cdc6 and Cdt1 expression 
in breast cancer cells.
To confirm these in vitro findings, we investigated the impact of letrozole treatment on the expression levels 
of Cdc6 and Cdt1 in breast cancer. From a dataset comprising 58 pairs of pre- and post-letrozole treatment 
specimens, pre- and post-letrozole specimens were analysed for Cdc6, Cdt1 and Orc1 expression. In this patient 
cohort, we found that expression level of Cdc6 was significantly lower post-letrozole than pre-letrozole (ANOVA 
test, p < 0.001; Fig. 7A). Similar results were observed for Cdt1 (ANOVA test, p = 0.003; Fig. 7B), but not for 
Orc1. In line with our in vitro experiments, inhibition of ER signalling resulted in reduced expression of Cdc6 
and Cdt1.
Interestingly, the expression level of Cdc6 was significantly lower in those patients who responded to the 
letrozole treatment than those patients who did not respond to treatment in the pre-treatment specimens 
Figure 5. The expression of Cdc6 and Cdt1 in breast cell lines. Histograms showing (A) Cdc6 and (B) Cdt1 
mRNA expression as measured by qPCR in normal breast epithelial cell line MCF10A, and two breast cancer 
cell lines, MCF7 and MDA MB231 in medium without Fetal Bovine Serum (FBS). (C) Western blot analysis of 
Cdc6, Cdt1 and β-actin in MCF10A, MCF7 and MDA MB231 cells in normal culture media (left panel) and in 
media without Fetal Bovine Serum (FBS; right panel).
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(post-hoc, Games-Howell test, p = 0.04; Fig. 7C). Similarly, there was a significantly higher expression of Cdc6 in 
the post-treatment specimens which responded to letrozole treatment than those which did not respond to the 
letrozole (post-hoc, Games-Howell test, p = 0.003; Fig. 7D). These results suggest that the expression level of Cdc6 
may predict the responsiveness of the breast cancer to inhibition of ER signalling.
Importantly, the association between Cdc6 and patient survival was only observed in ER positive breast cancer 
but not in ER negative breast cancer. While there was no significant difference in survival time between patients 
with breast cancer expressing a high level of Cdc6 and those expressing a low level of Cdc6 in ER-negative patients 
(Wilcoxon-Gehan test, p = 0.420; Fig. 4D), a high level of Cdc6 expression was significantly associated with a 
shorter survival time in breast cancer patients with ER positive breast cancer (Wilconxon-Gehan test, p = 0.004; 
Fig. 4E). No such correlation was observed for Cdt1 or for Orc1. These results suggest that Cdc6 may play a more 
important role in ER positive breast cancer and that breast cancer patients with ER positive status and a low level 
expression of Cdc6 may have a better prognosis as a result of better response to ER inhibition.
Discussion
Previously, we have shown that MCM2-7 genes, when overexpressed in breast cancer specimens confer a poor 
prognosis16. Since assembly of the pre-RC requires the presence of Cdc6 and Cdt14, it is highly possible that over-
expression of these two genes may also contribute to a poorer prognosis in breast cancer patients. Indeed, in the 
present study, we found that a high level expression of either Cdc6 or Cdt1 in the breast cancer specimens was 
associated with a shorter survival of the patients. Importantly, we observed a very strong correlation between the 
expression of Cdc6, Cdt1 and MCM2-7 genes. Our results suggest that these genes may cooperate in driving a 
more aggressive behaviour of breast cancer. In line with these results, Cdc6 and Cdt1 were expressed to a higher 
level in breast cancer cell lines than in normal breast epithelial cells, and they are suppressed by withdrawal of 
growth signal from the culture medium. Importantly, inhibition of ER signalling, which suppresses ER-positive 
breast cancer cell growth, decreased the expression of both Cdc6 and Cdt1 in vitro and in human breast cancer 
specimens, while lower expression of Cdc6 correlated with a better response of the tumour towards inhibition of 
ER signalling. In addition, we found that Cdc6 and Cdt1 expression levels were both higher in ER-negative breast 
cancer than ER-positive breast cancer, implying that increased Cdc6 and Cdt1 expression in ER- may contribute 
to increased aggressiveness; the results were also similar to MCM2-7 genes that we have previously described16.
It is well known that DNA replication is one very important step in cell proliferation, while increase in cell 
proliferation is one of the hallmarks in cancer development22. MCM2-7, Cdc6 and Cdt1 collaborate to regulate 
DNA replication, and each DNA replication licensing requires their sequential recruitment to the replication ori-
gin1. Increased expression of MCM confers poor prognosis in various cancer types, including breast cancer16, 18, 
lung cancer23, colon cancer24 and glioma25. However, the role of Cdc6 and Cdt1 in cancer development is less 
well understood. In the present report, we found that expression of Cdc6 and Cdt1 was positively correlated 
with MCM2-7 overexpression, while high levels expression of Cdc6 and Cdt1 were associated with poor prog-
nosis in breast cancer patients. Importantly, both Cdc6 and Cdt1 expression was increased in breast cancer cells 
Figure 6. The expression of Cdc6 and Cdt1 upon inhibition of ER signalling. (A) Histogram and (B) Western 
blot showing the expression of Cdc6 in MCF7 cells treated with tamoxifen at 0, 12 and 24 hours post-treatment. 
(C) Histogram and (D) Western blot showing the expression of Cdt1 in MCF7 cells treated with tamoxifen at 0, 
12 and 24 hours post-treatment.
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compared to normal cells, while their expression was upregulated by growth stimuli, such as FBS and estrogen, 
suggesting that these two genes are highly correlated with proliferation signal and may play an important role 
in promoting a more aggressive behaviour in breast cancer cells. However, since Cdc6, Cdt1 and Orc1 all play 
an important role in DNA replication licensing, the reasons for Orc1 mRNA expression not being a prognostic 
factor in breast cancer may be worth further investigation. Cdc6, or to a lesser extent Cdt1 but not that of Orc1, 
may be rate limiting factor in DNA replication licensing, which means that increased expression of Orc1 may not 
be resulting in increased rate of DNA replication. Otherwise, Orc1 may be regulated at its post-transcriptional or 
post-translational level instead of transcriptional level.
Estrogen has been shown to promote cell proliferation and enhance the expression of Cdc6 in cancer cells14, 
while previously, we have also demonstrated the association between ER and expression of MCM2-716. In the 
present study, we have shown that both Cdc6 and Cdt1 expression was supressed by inhibition of ER signalling 
both in vitro and in patients, suggesting that these two genes are downstream targets of the ER. In addition, the 
prognostic power of Cdc6 only reached statistical significant in ER-positive but not in ER-negative breast can-
cer, suggesting that ER-positive breast cancer may be more sensitive to limited replicative licensing. However, 
whether these two genes are direct targets of ER requires further investigation. Interestingly, the degree of Cdc6 
expression seemed to be correlatable with responsiveness of the cancer towards letrozole. This result strongly 
indicates that Cdc6 could also be a predictive biomarker for response to inhibition of estrogen receptor signalling 
therapy. Recent phase III clinical trials have shown that inhibition of HER226 or mTOR27 when combined with 
ER inhibition produced a better therapeutic response/outcome than ER inhibition alone. As breast cancer with a 
high level expression of Cdc6 were less responsive to ER inhibition, it is tempting to speculate that the modality of 
combining inhibitions of ER and other pathways may be more beneficial to patients with high level of Cdc6, who 
respond less well to ER inhibition alone.
Methods
Extraction of clinical and microarray gene expression data from breast cancer patient data-
sets. Seven breast cancer patient datasets, GSE145628, GSE203429, GSE314330, GSE349431, GSE739032, 
GSE1112133 and GSE1227634, with survival status available were included in our analyses; the combined dataset 
Figure 7. The expression of Cdc6 and Cdt1 in breast cancer specimens treated with letrozole. Error plots 
showing the expression levels of (A) Cdc6 and (B) Cdt1 in breast cancer specimens pre- and post-treatment 
with letrozole. Error plots showing the impact of ER signalling inhibition on the expression of Cdc6 in breast 
cancer specimens (C) pre-treatment and (D) post-treatment with letrozole.
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consisted of 1441 breast cancer patients; These cohorts were used in our previous study for investigating the prog-
nostic significance of MCMs in breast cancer16. One further breast cancer dataset, GSE546235, which comprises 
58 pairs of pre- and post-letrozole treatment specimens and associated response data available was also included. 
The data from these datasets were extracted from the Gene Expression Omnibus (GEO) database as previously 
described16. The datasets used in the current study are all publicly available and the links to access these datasets 
are listed in Supplementary Table 1. Patients were divided into four groups based on the expression levels of genes 
of interest using upper quartile, median and lower quartile expression levels as the cut-off points. In Kaplan-Meier 
analysis where patients were divided into two groups, median expression level was used as the cut-off point.
Statistical analysis for breast cancer datasets. The statistical analysis was performed using SPSS19.0. 
The associations between expression levels of genes were analyzed by Chi-Square test while the correlations 
between expression levels of genes were analyzed by Spearman’s rank test. The associations between expres-
sion levels of genes and survival were analyzed by Kaplan-Meier analysis compared by Wilcoxon-Gehen test. 
Univariate and Multivariate Cox-regression analyses were used to identify independent predictors for patient 
survival using a forward stepwise approach with an entry limit of p < 0.05. The difference in the expression levels 
of genes of interest pre- or post-letrozole treatment was compared by repeated measure ANOVA, while the dif-
ference in expression level of genes in specimens with different response to letrozole was compared by ANOVA. 
Results were considered significant when p-value was smaller than 0.05.
Cell Culture and treatment. The human breast carcinoma cell lines (MCF7, MCF10A, MDA MB231) were 
purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). MCF7 and MDA MB231 cells 
were maintained in Dulbecco’s minimal essential medium (DMEM) (Gibco) supplemented with 10% fetal bovine 
serum (FBS, Gibco), 4 mM L-glutamine (Gibco), 1% penicillin-streptomycin (Gibco), and sodium pyruvate 
(1 mM). For MCF7 cells, medium was as above, with the addition of 0.01 mg/ml bovine insulin (Sigma). MCF10A 
cells were maintained in DMEM medium supplemented with 5% FBS (Gibco), 1% penicillin-streptomycin 
(Gibco), 20 ng/ml EGF (Peprotech), 0.5 ug/ml hydrocortisone (Sigma), 100ng cholera toxin (Sigma) and 10 ug/
ml bovine insulin (Sigma). All cells were cultured at 37 °C in a humidified atmosphere of 95% air and 5% CO2. For 
serum starvation, cells were cultured in respective media without FBS and without phenol red.
For tamoxifen treatment, MCF7 cells were treated with 18 uM tamoxifen (Sigma). The cells were harvested at 
0, 12, 24 hours and protein and gene expression was quantified by Western blot and qRT-PCR respectively.
Western blot. Cells were harvested using a cell scraper and suspended in RIPA buffer (150 mM NaCl; 5 mM 
EDTA, 50 mM Tris, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with protease inhib-
itor (Roche) and phosphatase inhibitor (Roche). Endogenous proteins from whole cell extracts were isolated 
by sonication followed by centrifugation. Proteins were quantified using BCA protein assay (ThermoFisher 
Scientific) and equal amounts of proteins were loaded onto 4–12% SDS–polyacrylamide gel electrophoresis 
(SDS–PAGE) gels and electrophoretically transferred to a PDVF membrane using Novex iBlot transfer stack 
(ThermoFisher Scientific) on a iBlot gel transfer device (ThermoFisher Scientific). The membrane containing 
the transferred protein was blocked with 5% BSA at room temperature for 1 h. Target proteins were detected by 
incubating the membrane at 4 °C overnight with primary anti-Cdt1 antibody (#8064 Cell Signaling Technology) 
(1:500) or anti-Cdc6 antibody (#3387 cell signaling technology) (1:500) and primary anti-β-actin antibody (Santa 
Cruz) (1:5000). Blot was further developed using horseradish peroxidase (HRP)-conjugated secondary antibod-
ies (1:5000) (Santa Cruz) and detected using Immobilon Western Chemilum HRP substrate (Merck). Blots were 
visualized on a ChemiDoc Touch Imaging System (BioRad).
Quantitative RT-PCR. Cells were harvested by cell scraping in RLT lysis buffer and total RNA was isolated 
using RNeasy Mini Kit (Qiagen). RNA quantity and quality were measured using a Nanodrop™ spectropho-
tometer (NanoDrop products). First strand cDNA synthesis was performed from 1 μg total RNA using a High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) on a BioRad C1000 TouchTM Thermal Cycler. 
qRT-PCR analysis was performed using TaqMan® Universal PCR Master Mix (Applied Biosystems) and Taqman 
probes specific for Cdc6 (HS00154374_m1), Cdt1 (HS00368864_m1) and GAPDH (Hs02758991_g1) purchased 
from ThermoFisher Scientific. The analysis was performed using a Mx3005 P qPCR System (Agilent) thermocy-
cler. The differences observed between the control and treated groups for qRT-PCR were analyzed by unpaired 
Student’s t-test (two-tailed) using GraphPad Prism 6 (GraphPad Software). The results were expressed as the 
Mean ± SEM (standard error of mean) from three different replicates and a value of p < 0.05 was considered 
statistically significant.
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